MicroRNAs在急性心肌梗死诊断及预后中的研究进展

摘要
图/表
参考文献(40)
相关文章 (15)

全文: PDF (536 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要急性心肌梗死（AMI）是世界范围内最常见的心血管急症之一，具有较高的发病率和死亡率。早期和准确的诊断可以减缓AMI的发展，降低死亡率。微小RNA（miRNAs）通过影响心肌细胞增殖、凋亡和自噬等过程，参与心肌梗死后血管重塑。越来越多的研究证实，miRNAs异常表达可作为AMI患者的诊断和预后的生物标志物，对AMI患者的治疗可能具有重要的临床意义。本文综述了miRNAs在AMI中的治疗作用的最新进展，同时总结了miRNAs作为AMI诊断和预后生物标志物的潜在应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李奕帛赵国安孟卫正王秀珑李东旭林飞

关键词 ：急性心肌梗死, 微小RNA, 心肌重塑

Abstract：Acute myocardial infarction (AMI) is one of the most common cardiovascular emergencies in the world, with high morbidity and mortality. Early and accurate diagnosis can slow down the development of AMI and reduce the mortality. MicroRNAs (miRNAs) are involved in vascular remodeling after myocardial infarction by affecting myocardial cell proliferation, apoptosis and autophagy. More and more studies have confirmed that abnormal expression of miRNAs can be used as biomarkers for diagnosis and prognosis in patients with AMI, which may have important clinical significance for the treatment of AMI patients. This article reviews the recent advances in the therapeutic role of miRNAs in AMI, and summarizes the potential use of miRNAs as biomarkers for the diagnosis and prognosis of AMI.

Key words： Acute myocardial infarction MicroRNA Myocardial remodeling

基金资助:河南省医学科技攻关计划（联合共建）项目（LH GJ20190441、LHGJ20190442、LHGJ20190471）；
河南省高等学校重点科研项目（21A320012）。

通讯作者: 林飞（1972.7-），女，博士，博士后，副主任中医师，新乡医学院第一附属医院心脏中心副主任；研究方向：中西医结合冠心病防治。

作者简介: 李奕帛（1994.10-），女，新乡医学院第一附属医院2018级内科学专业在读硕士研究生；研究方向：中西医结合冠心病防治。

引用本文:

李奕帛赵国安孟卫正王秀珑李东旭林飞. MicroRNAs在急性心肌梗死诊断及预后中的研究进展[J]. 中国医药导报, 2021, 18(24): 44-47.
LI Yibo ZHAO Guoan MENG Weizheng WANG Xiulong LI Dongxu LIN Fei. Research progress of microRNAs in the diagnosis and prognosis of acute myocardial infarction. 中国医药导报, 2021, 18(24): 44-47.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I24/44

[1] Guo J，Liu HB，Sun C，et al. MicroRNA-155 Promotes Myocardial Infarction-Induced Apoptosis by Targeting RNA-Binding Protein QKI [J]. Oxid Med Cell Longev，2019， 2019：4579806.
[2] Vogel B，Keller A，Frese KS，et al. Refining diagnostic microRNA signatures by whole-miRNome kinetic analysis in acute myocardial infarction [J]. Clin Chem，2013，59（2）：410-418.
[3] Zhou SS，Jin JP，Wang JQ，et al. miRNAS in cardiovascular diseases：potential biomarkers，therapeutic targets and challenges [J]. Acta Pharmacol Sin，2018，39（7）：1073-1084.
[4] Mussbacher M，Krammer TL，Heber S，et al. Impact of Anticoagulation and Sample Processing on the Quantification of Human Blood-Derived microRNA Signatures [J]. Cells，2020，9（8）：1915.
[5] Fasolo F，Di Gregoli K，Maegdefessel L，et al. Non-coding RNAs in cardiovascular cell biology and atherosclerosis [J]. Cardiovasc Res，2019，115（12）：1732-1756.
[6] Zhu L，Li N，Sun L，et al. Non-coding RNAs：The key detectors and regulators in cardiovascular disease [J]. Genomics，2021，113（1 Pt 2）：1233-1246.
[7] Li Y，Lu J，Bao X，et al. MiR-499-5p protects cardiomyocytes against ischaemic injury via anti-apoptosis by targeting PDCD4 [J]. Oncotarget，2016，7（24）：35607-35617.
[8] Wang J，Jia Z，Zhang C，et al. miR-499 protects cardiomyocytes from H2O2-induced apoptosis via its effects on Pdcd4 and Pacs2 [J]. RNA Biol，2014，11（4）：339-350.
[9] Zhang XY，Huang Z，Li QJ，et al. Ischemic postconditioning attenuates the inflammatory response in ischemia/reperfusion myocardium by upregulating miR-499 and inhibiting TLR2 activation [J]. Mol Med Rep，2020，22（1）：209-218.
[10] Zhou R，Huang W，Fan X，et al. miR-499 released during myocardial infarction causes endothelial injury by targeting α7-nAchR [J]. J Cell Mol Med，2019，23（9）：6085-6097.
[11] Hromádka M，■erná V，Pe?觢ta M，et al. Prognostic Value of MicroRNAs in Patients after Myocardial Infarction：A Substudy of PRAGUE-18 [J]. Dis Markers，2019，2019：2925019.
[12] Chen X，Zhang L，Su T，et al. Kinetics of plasma microRNA-499 expression in acute myocardial infarction [J]. J Thorac Dis，2015，7（5）：890-896.
[13] Li N，Zhou H，Tang Q. miR-133：A Suppressor of Cardiac Remodeling？ [J]. Front Pharmacol，2018，9：903.
[14] Sun B，Liu S，Hao R，et al. RGD-PEG-PLA Delivers MiR-133 to Infarct Lesions of Acute Myocardial Infarction Model Rats for Cardiac Protection [J]. Pharmaceutics，2020，12（6）：575.
[15] Chen Y，Zhao Y，Chen W，et al. MicroRNA-133 overexpression promotes the therapeutic efficacy of mesenchymal stem cells on acute myocardial infarction [J]. Stem Cell Res Ther，2017，8（1）：268.
[16] Moghiman T，Barghchi B，Esmaeili SA，et al. Therapeutic angiogenesis with exosomal microRNAs：an effectual approach for the treatment of myocardial ischemia [J]. Heart Fail Rev，2021，26（1）：205-213.
[17] Yu Y，Liu H，Yang D，et al. Aloe-emodin attenuates myocardial infarction and apoptosis via up-regulating miR-133 expression [J]. Pharmacol Res，2019，146：104315.
[18] Peng L，Chun-guang Q，Bei-fang L，et al. Clinical impact of circulating miR-133，miR-1291 and miR-663b in plasma of patients with acute myocardial infarction [J]. Diagn Pathol，2014，9：89.
[19] Li C，Pei F，Zhu X，et al. Circulating microRNAs as novel and sensitive biomarkers of acute myocardial Infarction [J]. Clin Biochem，2012，45（10/11）：727-732.
[20] Liu L，Yuan Y，He X，et al. MicroRNA-1 upregulation promotes myocardiocyte proliferation and suppresses apoptosis during heart development [J]. Mol Med Rep，2017，15（5）：2837-2842.
[21] Su T，Shao X，Zhang X，et al. Circulating microRNA-1 in the diagnosis and predicting prognosis of patients with chest pain：a prospective cohort study [J]. BMC Cardiovasc Disord，2019，19（1）：5.
[22] Ewelina K，Eljaszewicz A，Kazimierczyk R，et al. Altered microRNA dynamics in acute coronary syndrome [J]. Postepy Kardiol Interwencyjnej，2020，16（3）：287-293.
[23] Parahuleva MS，Euler G，Mardini A，et al. Publisher Correction：Identification of microRNAs as potential cellular monocytic biomarkers in the early phase of myocardial infarction：a pilot study [J]. Sci Rep，2018，8（1）：6052.
[24] Ma Q，Ma Y，Wang X，et al. Circulating miR-1 as a potential predictor of left ventricular remodeling following acute ST-segment myocardial infarction using cardiac magnetic resonance [J]. Quant Imaging Med Surg，2020， 10（7）：1490-1503.
[25] Oliveira-Carvalho V，Carvalho VO，Bocchi EA. The emerging role of miR-208a in the heart [J]. DNA Cell Biol，2013，32（1）：8-12.
[26] Yan X，Liu J，Wu H，et al. Impact of miR-208 and its Target Gene Nemo-Like Kinase on the Protective Effect of Ginsenoside Rb1 in Hypoxia/Ischemia Injuried Cardiomyocytes [J]. Cell Physiol Biochem，2016，39（3）：1187-1195.
[27] Liu X，Fan Z，Zhao T，et al. Plasma miR-1，miR-208，miR-499 as potential predictive biomarkers for acute myocardial infarction：An independent study of Han population [J]. Exp Gerontol，2015，72：230-238.
[28] Han Z，Zhang L，Yuan L，et al. Change of plasma microRNA-208 level in acute myocardial infarction patients and its clinical significance [J]. Ann Transl Med，2015，3（20）：307.
[29] Montgomery RL，Hullinger TG，Semus HM，et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure [J]. Circulation，2011， 124（14）：1537-1547.
[30] Callis TE，Pandya K，Seok HY，et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice [J]. J Clin Invest，2009，119（9）：2772-2786.
[31] Ren Y，Bao R，Guo Z，et al. miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A [J]. Exp Ther Med，2021，21（1）：67.
[32] Wang F，Long G，Zhao C，et al. Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction [J]. PLoS One，2014，9（9）：e105734.
[33] Yang B，Dong R，Zhao H. Inhibition of microRNA-346 inhibits myocardial inflammation and apoptosis after myocardial infarction via targeting NFIB [J]. Eur Rev Med Pharmacol Sci，2020，24（22）：11752-11760.
[34] Goren Y，Kushnir M，Zafrir B，et al. Serum levels of microRNAs in patients with heart failure [J]. Eur J Heart Fail，2012，14（2）：147-154.
[35] Osbourne A，Calway T，Broman M，et al. Downregulation of connexin43 by microRNA-130a in cardiomyocytes results in cardiac arrhythmias [J]. J Mol Cell Cardiol，2014， 74：53-63.
[36] Jiang J，Li P，Ling H，et al. MiR-499/PRDM16 axis modulates the adipogenic differentiation of mouse skeletal muscle satellite cells [J]. Hum Cell，2018，31（4）：282-291.
[37] Li W，Zhong Y，Shuang Y，et al. High concentration of miR-133 is a useful marker for the diagnosis of lymphoma- associated hemophagocytic syndrome [J]. Cancer Biomark，2017，20（2）：159-164.
[38] Hesari A，Azizian M，Darabi H，et al. Expression of circulating miR-17，miR-25，and miR-133 in breast cancer patients [J]. J Cell Biochem，2018. DOI：10.1002/jcb.27984. Epub ahead of print.
[39] Li M，Zhang S，Wu N，et al. Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3 [J]. Sci Rep，2016，6：23100.
[40] Zhang J，Wang L，Mao S，et al. miR-1-3p Contributes to Cell Proliferation and Invasion by Targeting Glutaminase in Bladder Cancer Cells [J]. Cell Physiol Biochem，2018，51（2）：513-527.